- Report
- October 2025
- 150 Pages
Global
From €4320EUR$4,850USD£3,738GBP
- Report
- October 2025
- 150 Pages
Global
From €4320EUR$4,850USD£3,738GBP
- Report
- October 2025
- 150 Pages
Global
From €4320EUR$4,850USD£3,738GBP
- Report
- August 2025
- 150 Pages
Global
From €4320EUR$4,850USD£3,738GBP
- Report
- November 2025
- 150 Pages
Global
From €4320EUR$4,850USD£3,738GBP
- Report
- November 2025
- 150 Pages
Global
From €4320EUR$4,850USD£3,738GBP
- Report
- November 2025
- 150 Pages
Global
From €4320EUR$4,850USD£3,738GBP
- Report
- October 2025
- 160 Pages
Global
From €2990EUR$3,358USD£2,588GBP
€3518EUR$3,950USD£3,044GBP
- Report
- October 2025
- 98 Pages
Global
From €3500EUR$4,210USD£3,135GBP
- Report
- September 2025
- 150 Pages
Global
From €3963EUR$4,450USD£3,430GBP
- Report
- August 2025
- 277 Pages
Global
From €3963EUR$4,450USD£3,430GBP
- Report
- May 2026
- 170 Pages
United States
From €4320EUR$4,850USD£3,738GBP
- Report
- February 2026
- 150 Pages
United States
From €4320EUR$4,850USD£3,738GBP
- Report
- February 2025
- 138 Pages
Global
From €2000EUR$2,405USD£1,791GBP
- Report
- June 2022
- 1500 Pages
Global
From €3474EUR$3,900USD£3,006GBP
- Drug Pipelines
- March 2022
- 900 Pages
Global
From €8016EUR$9,000USD£6,936GBP
- Report
- February 2022
- 360 Pages
United States
From €3206EUR$3,600USD£2,775GBP
- Report
- November 2021
- 222 Pages
Global
From €2672EUR$3,000USD£2,312GBP
- Report
- June 2020
- 753 Pages
Global
From €2939EUR$3,300USD£2,543GBP
- Report
- November 2024
- 301 Pages
Global
From €4008EUR$4,500USD£3,468GBP

Pembrolizumab is a type of oncology drug used to treat certain types of cancer. It is a monoclonal antibody, which works by targeting and blocking a protein called PD-1, which is found on the surface of some cancer cells. This helps the body's immune system to recognize and attack the cancer cells. Pembrolizumab is used to treat a variety of cancers, including melanoma, non-small cell lung cancer, head and neck cancer, Hodgkin lymphoma, and urothelial carcinoma. It is also used in combination with other drugs to treat certain types of advanced or metastatic cancers.
Pembrolizumab is approved by the US Food and Drug Administration (FDA) and is available in the US and other countries. It is typically administered intravenously, and the dosage and duration of treatment depend on the type and stage of cancer being treated.
Some companies in the Pembrolizumab market include Merck & Co., Inc., Bristol-Myers Squibb, AstraZeneca, and Roche. Show Less Read more